Mood Disorders
|
0.300 |
Biomarker
|
group |
PSYGENET |
These results provide evidence that selective inhibition of HDAC1 and HDAC2 in brain may provide an epigenetic-based target for developing improved treatments for mood disorders and other brain disorders with altered chromatin-mediated neuroplasticity.
|
23967191 |
2013 |
PULMONARY HYPERTENSION, PRIMARY, DEXFENFLURAMINE-ASSOCIATED
|
0.300 |
Biomarker
|
disease |
CTD_human |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
Pulmonary Hypertension, Primary, Fenfluramine-Associated
|
0.300 |
Biomarker
|
disease |
CTD_human |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
Hematopoetic Myelodysplasia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Effects of arsenic disulfide on apoptosis, histone acetylation, toll like receptor 2 activation, and erythropoiesis in bone marrow mononuclear cells of myelodysplastic syndromes patients in vitro.
|
28963909 |
2017 |
Idiopathic pulmonary arterial hypertension
|
0.300 |
Biomarker
|
disease |
CTD_human |
HDAC1 and HDAC5 protein levels were elevated in lungs from human idiopathic pulmonary arterial hypertension and in lungs and right ventricles from rats exposed to hypoxia.
|
22711276 |
2012 |
Pulmonary Hypertension, Primary, 1, With Hereditary Hemorrhagic Telangiectasia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
Pulmonary Hypertension, Primary, 1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
Cerebrovascular accident
|
0.210 |
Biomarker
|
group |
BEFREE |
Collectively, these results demonstrate that NCX1 expression is regulated by the Sp3/REST/HDAC1/HDAC2 complex in tMCAO and by the Sp1/HIF-1/p300 complex in PC+tMCAO and that epigenetic intervention, by modulating the acetylation of ncx1-Br, may be a strategy for the development of innovative therapeutic intervention in stroke.
|
25972164 |
2015 |
Cerebrovascular accident
|
0.210 |
Biomarker
|
group |
RGD |
Double immunohistochemistry analysis revealed that stroke substantially increased the number of NG2+OPCs with nuclear HDAC1 and HDAC2 immunoreactivity and cytoplasmic HDAC4 which were associated with augmentation of proliferating OPCs, as determined by BrdU and Ki67 double reactive cells after stroke.
|
24657831 |
2014 |
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
|
19553350 |
2009 |
Fetal Growth Retardation
|
0.200 |
Biomarker
|
phenotype |
RGD |
Prenatal caffeine ingestion induces aberrant DNA methylation and histone acetylation of steroidogenic factor 1 and inhibits fetal adrenal steroidogenesis.
|
24717552 |
2014 |
Fetal Growth Retardation
|
0.200 |
Biomarker
|
phenotype |
RGD |
Uteroplacental insufficiency affects epigenetic determinants of chromatin structure in brains of neonatal and juvenile IUGR rats.
|
16380407 |
2006 |
Fetal Growth Retardation
|
0.200 |
Biomarker
|
phenotype |
RGD |
The fetal IUGR state was characterized by loss of USF-1 binding at the proximal promoter of Pdx1, recruitment of the histone deacetylase 1 (HDAC1) and the corepressor Sin3A, and deacetylation of histones H3 and H4.
|
18464933 |
2008 |
Pulmonary Hypertension
|
0.200 |
Biomarker
|
phenotype |
RGD |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
Right Ventricular Hypertrophy
|
0.200 |
Biomarker
|
disease |
RGD |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hypermethylation of APC, HDAC1, and GSK1 genes has been previously reported in more than one study on tissue samples of breast cancer.
|
28349825 |
2017 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer.
|
25173798 |
2014 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we sought to investigate the CSC-specific function of HDAC1 and HDAC7 mechanistically by using a stem-like breast cancer (BrCa) cell model BPLER and matched nonstem tumor cell (nsTC)-like HMLER, along with conventional BrCa cell lines with different CSC enrichment levels.
|
31375747 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer.
|
23421821 |
2013 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, repression complex including DNMT1, HDAC1 and MeCP2 is only associated with silenced ESR1 in ER-negative MDA-MB-468 human breast cancer cells.
|
21655924 |
2012 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2.
|
29988076 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study is the first to investigate the combinatorial effects of low physiologically achievable concentrations of WA and SFN on breast cancer cell proliferation, histone deacetylase1 (HDAC1) and DNA methyltransferases (DNMTs).
|
28534825 |
2017 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer.
|
12789259 |
2003 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings validate that 32c is a potent dual inhibitor of HDAC1/6 that can be an efficacious treatment for breast cancer with Adriamycin resistance.
|
30251407 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Stabilized Peptide HDAC Inhibitors Derived from HDAC1 Substrate H3K56 for the Treatment of Cancer Stem-Like Cells <i>In Vivo</i>.
|
30842103 |
2019 |